Newsroom Join our team About us Our purpose Our culture Products & pipeline Investors Overview Our leadership Our journey Grants & giving Contact us Join our team Our leadership Meet the senior leaders guiding Adamas Naomi, person with Parkinson’s & origami enthusiast The Adamas executive team and board of directors are comprised of industry veterans, each dedicated to our vision of delivering innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. Our executive team Neil F. McFarlane Chief Executive Officer “I am proud to lead an organization with incredible passion and commitment to making a difference to people living with neurological diseases. ‘Patient First’ is more than a value to us, it’s the driving force behind our decisions, and our desire to bring additional benefits to the healthcare community.” Biography Jill Jene Head of Corporate Development, Strategy, Portfolio Planning and Alliance Management “I’m passionate about growth and am motivated to see this passion embraced by everyone at Adamas. It’s exciting to work at a company that has a culture of being open to new ideas, knowing that our contributions can have a long-term impact on patients and all our stakeholders.” Biography Sarah Mathieson Head of Corporate Communications, Patient Advocacy and Engagement “We are in the position where our work can help people live better lives each day, and that’s an incredible privilege. It forms a foundation for how we work together. There’s a real sense of wanting to deliver excellence and to strive to improve so we can continue to grow our company and do even more in the future.” Biography Christopher B. Prentiss Chief Financial Officer “Adamas is a place for growth for both careers and ideas. We have a culture where great ideas can come from anywhere in the company. Our philosophy is, if you come here, it is because you want to contribute, grow personally, and make Adamas a success.” Biography Adrian Quartel, MD Chief Medical Officer “I thrive on working in a place where scientific exploration and creativity are encouraged and very much a part of the company culture. Research at Adamas is forward-thinking and always has the end goal in mind – providing healthcare professionals with meaningful medicines that can make a significant impact on their patients.” Biography Eric Schlezinger Head of Human Resources “When people interview here they have something in common – they’re looking to make an impact. I was motivated to join Adamas to help our people deliver their best work today, and grow into the opportunities that may arise tomorrow.” Biography Vijay Shreedhar Chief Commercial Officer “I am energized by the opportunity to commercialize a meaningful treatment option for patients with significant unmet need and doing so in a culture of collaboration and innovation. Our culture gives everyone here the opportunity to be heard while reinforcing that all of our work impacts the daily lives of the patients who rely on us.” Biography Our board of directors David L. Mahoney Chairman Mr. Mahoney is a private equity investor and currently serves on the board of directors of Corcept Therapeutics and Mercy Corps, and as a Trustee of the Schwab Mutual Funds and ETFs, Mount Holyoke College, and SFMOMA. Previously, Mr. Mahoney acted as Co-chief Executive Officer of McKesson HBOC, Inc. (now McKesson Corporation) and as Chief Executive Officer of McKesson LLC from July 1999 to February 2001. He joined McKesson in 1990 as Vice President for Strategic Planning and managed the company’s relationships with the pharmaceutical industry. Prior to joining McKesson, Mr. Mahoney was a principal with McKinsey & Company from 1981 to 1990. Mr. Mahoney is an honors graduate of Harvard Business School and Princeton University. Neil F. McFarlane Chief Executive Officer Neil joined Adamas as Chief Executive Officer and member of the Board of Directors in September 2019. He brings over two decades of global biopharmaceutical and life sciences experience delivering value to patients suffering from serious illnesses. Neil has delivered growth in both specialty and orphan products in the United States, Europe, Asia, and Latin America. He most recently served as Chief Operating Officer of Retrophin, Inc. with principal responsibility for global commercial operations, corporate development, patient services, and program and alliance management. Previously he held executive and general management positions at leading biopharmaceutical companies, including UCB, Genzyme, and Sangstat Medical Corporation. Neil served as an officer and enlisted soldier in the United States Army Reserves. He holds a B.S. and M.S. in Nursing from the University of Florida. Michael F. Bigham Mr. Bigham is currently Executive Chairman of the Board at Paratek Pharmaceutical Inc. He was Chief Executive Officer and Chairman of the Board of Directors at Paratek from 2014 to June 2019. He is also currently Director of the Frazier Life Sciences Acquisition Corporation. He has more than 25 years of senior leadership experience in the biopharmaceutical industry. From 2003 to 2015, Mr. Bigham was a partner at Abingworth LLP, an international investment group dedicated to life sciences and healthcare. Earlier in his career, he served as Chairman and Chief Executive Officer of Coulter Pharmaceuticals up until the company’s acquisition by Corixa. Mr. Bigham was formerly Chairman of the board of directors of InMediata and has held several directorships, including Avila Therapeutics, Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals, Avedro, and Valeritas. He received his BS from the University of Virginia and his MBA from Stanford University. Martha J. Demski Ms. Demski has more than 30 years of experience in the fields of finance and biotechnology. She is chair of the board of directors of Chimerix, where she also serves as a member of the audit committee. She also chairs the audit committee and serves on the compensation committee at ADMA Biologics and Equillium. Previously, Ms. Demski served as Senior Vice President and Chief Financial Officer of Ajinomoto Althea, Inc., as well as interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center. She has also served as Chief Financial Officer of Vical Incorporated, where she was responsible for multiple private and public financings, including the company’s initial public offering. Additionally, Ms. Demski also has more than 13 years of banking experience with Bank of America. She holds an MBA from The University of Chicago Booth School of Business and a BA from Michigan State University. In 2014 Ms. Demski was awarded the CFO of the Year Award of Distinction by the San Diego Business Journal. In 2017 Ms. Demski was honored as the Director of the Year in Corporate Governance by the San Diego Corporate Directors Forum. William Ericson, JD Mr. Ericson is a managing partner of Mohr Davidow Ventures and a managing director of Wildcat Venture Partners. He currently serves on the board of directors of Pacific Biosciences and Rocket Fuel, as well as the boards of a number of privately-held software and healthcare companies. Mr. Ericson received his BSFS from Georgetown University of Foreign Service and his JD from Northwestern University School of Law. John MacPhee, MPH Mr. MacPhee serves as Chief Executive Officer of The JED Foundation, a nonprofit organization that exists to reduce the risks of substance abuse, self-harm, and suicide, and to help young adults thrive. Prior to JED, he served as Executive Vice President of Par Pharmaceutical and President of Par’s Strativa Pharmaceuticals division, where he oversaw commercial operations, clinical development, medical affairs, and business development. Previously, he worked at Forest Laboratories, where he led the launches of Celexa® (citalopram), Lexapro® (escitalopram), and Namenda® (memantine HCl). Mr. MacPhee also serves as a board member for Bottom Line, a nonprofit organization that provides guidance counseling to disadvantaged urban youth to help them get into college and graduate. He earned a BA from Columbia College, an MBA from New York University, and an MPH from Columbia University. Spyros Papapetropoulos, MD, PhD Dr. Papapetropoulos is a board-certified neurologist with over 20 years of academic and industry experience in neurology and neurosciences. He has deep experience in neurodegenerative diseases and movement disorders and in bringing multiple neurological therapies to market. Since leaving academia, Dr. Papapetropoulos has held R&D and scientific leadership roles at leading neurological companies including Acadia, Teva, Pfizer, Allergan, and Biogen. He is currently Chief Medical Officer for Vigil Neuro. Dr. Papapetropoulos was trained in Queen’s Square, London, UK and holds appointments as Consultant with Massachusetts General Hospital and Voluntary Professor of Neurology with the University of Miami, Miller School of Medicine. Anna Richo, JD Anna Richo, J.D., is General Counsel, Chief Compliance Officer, and Corporate Secretary at Cargill, Inc. Ms. Richo brings over 30 years of leadership experience managing legal and compliance functions within the biotechnology and pharmaceutical industry, including UCB, Amgen and Baxter Healthcare as well as prior public-company Board, Audit and Finance Committee experience at Cytyc Corporation. Ms. Richo’s successful career path includes leadership roles in biotechnology and pharmaceutical companies as general counsel and leading compliance, intellectual property and corporate litigation. Ms. Richo has previously been recognized as one of the ’Top 15 Women in Pharma’. She holds a bachelor’s degree in industrial and labor relations from Cornell University and a J.D. degree from DePaul University College of Law. She is a member of the Board of Trustees for DePaul University. Adamas recognized by 2020 Women on Boards The organization 2020 Women on Boards named Adamas as a Winning ‘W’ Company for both 2019 and 2020 for having more than 20% women on our Board of Directors. 2020 Women on Boards is a nonprofit education campaign which advocates globally to increase the number of women on corporate boards to at least 20% by 2020. The organization educates corporate stakeholders on the importance of board diversity, and they have recognized Adamas as an example of enlightened corporate governance. Connect with us Contact us Privacy policy Online tracking opt-out guide Terms of use Site map © 2021 Copyright Adamas Pharmaceuticals, Inc. or its related companies. All rights reserved. Please note that our Privacy Policy has recently been updated: Privacy PolicyACCEPT